Journal Article Summary
The article investigates the use of mirtazapine, an antidepressant, as an additional treatment for individuals with schizophrenia. Schizophrenia is a serious mental health condition characterized by a range of symptoms, including delusions, hallucinations, and difficulties with emotional expression and motivation. While antipsychotic medications are the primary treatment for schizophrenia, they often do not fully address negative symptoms, which can significantly impact a person's quality of life. Therefore, exploring adjunct treatments like mirtazapine is important to potentially enhance overall treatment outcomes.
The researchers conducted a systematic review of nine randomized controlled trials involving 310 participants, comparing mirtazapine plus standard care to placebo plus standard care. The findings suggest that adding mirtazapine may lead to slight improvements in overall mental state and reduce symptoms of akathisia, a common side effect of antipsychotics. However, there was no significant evidence that mirtazapine effectively addressed negative symptoms or improved global functioning. Additionally, participants taking mirtazapine experienced a higher risk of weight gain and sedation, indicating potential side effects that need to be considered.
Despite some positive indications, the evidence supporting mirtazapine's effectiveness is primarily of very low quality, making it difficult to draw firm conclusions about its role in treating schizophrenia. Patients and caregivers should be cautious and discuss these findings with healthcare professionals before considering mirtazapine as an adjunct treatment. It is crucial to weigh the potential benefits against the risks and to stay informed about ongoing research that may provide clearer insights into the safety and efficacy of mirtazapine for this condition.
Medication Safety Note
This journal article summary is provided for educational purposes only and is not medical advice. Always consult a licensed healthcare professional before starting, stopping, or changing any medication.
Article Cited
- Perry Luke A, Ramson Dhruvesh, Stricklin Suzanne. Mirtazapine adjunct for people with schizophrenia. The Cochrane Database of Systematic Reviews 2018. DOI: 10.1002/14651858.CD011943.pub2. PMID: 29802811. PMCID: PMC6494505.
Featured Pill Pals Product
Mirtazapine 15 mg Tablets --- 30 Count --- Generic for Remeron --- Rising Pharma
Mirtazapine 15 mg Tablets — 30 Count — Generic for Remeron — Rising Pharma is available through Pill Pals Pharmacy with cash-pay pharmacy pricing and free shipping where available. Prescription required.
Request a prescription transfer and our pharmacy team will help coordinate the next step.
